Posted by Michael Wonder on 03 Aug 2022
FDA approves Coherus’ Cimerli (ranibizumab-eqrn) as the first and only interchangeable biosimilar to Lucentis for all five indications, with 12 months of interchangeability exclusivity
2 August 2022 - First Cimerli product sales expected in October 2022.
Coherus BioSciences announced today that the U.S. FDA has approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all five indications, meeting the FDA’s rigorous standards to the reference product, including safety, efficacy and quality.
